Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00153_DB00169_nanopub.RAbN0chkkw1F2VPqcip4t0DbGi2q3qUdkO7rVHGBeE99c#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00153_DB00169 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00153_DB00169 label "DDI between Ergocalciferol and Cholecalciferol - Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. [drugbank_resource:DB00153_DB00169]" assertion.
- drugbank_resource:DB00153_DB00169 identifier "drugbank_resource:DB00153_DB00169" assertion.
- drugbank_resource:DB00153_DB00169 title "DDI between Ergocalciferol and Cholecalciferol - Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity." assertion.
- drugbank:DB00169 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00153_DB00169 assertion.
- drugbank:DB00153 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00153_DB00169 assertion.